Literature DB >> 12233981

Neurocognitive impairment associated with alcohol use disorders: implications for treatment.

Marsha E Bates1, Stephen C Bowden, Danielle Barry.   

Abstract

Between 50% and 80% of individuals with alcohol use disorders experience mild to severe neurocognitive impairment. There is a strong clinical rationale that neurocognitive impairment is an important source of individual difference affecting many aspects of addiction treatment, but empirical tests of the direct influence of impairment on treatment outcome have yielded weak and inconsistent results. The authors address the schism between applied-theoretical perspectives and research evidence by suggesting alternative conceptual models of the relationship between neurocognitive impairment and addiction treatment outcome. Methods to promote neurocognitive recovery and ways in which addiction treatments may be modified to improve psychosocial adaptation are suggested. Specific suggestions for future research that may help clarify the complex relations between neurocognitive impairment and addiction treatment are outlined.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12233981     DOI: 10.1037//1064-1297.10.3.193

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  109 in total

1.  Comparisons of Korsakoff and non-Korsakoff alcoholics on neuropsychological tests of prefrontal brain functioning.

Authors:  Marlene Oscar-Berman; Shalene M Kirkley; David A Gansler; Ashley Couture
Journal:  Alcohol Clin Exp Res       Date:  2004-04       Impact factor: 3.455

2.  The occurrence of neurological symptoms in currently abstinent misusers of alcohol.

Authors:  M T Khalily; B Hallahan
Journal:  Ir J Med Sci       Date:  2012-01-14       Impact factor: 1.568

3.  Gut region-dependent alterations of nitrergic myenteric neurons after chronic alcohol consumption.

Authors:  Mária Bagyánszki; Nikolett Bódi
Journal:  World J Gastrointest Pathophysiol       Date:  2015-08-15

Review 4.  Executive Functioning in Alcohol Use Studies: A Brief Review of Findings and Challenges in Assessment.

Authors:  Anne M Day; Christopher W Kahler; David C Ahern; Uraina S Clark
Journal:  Curr Drug Abuse Rev       Date:  2015

5.  Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study.

Authors:  Roman Shrestha; Frederick L Altice; Brian Sibilio; Jude Ssenyonjo; Michael M Copenhaver
Journal:  Contemp Clin Trials       Date:  2019-06-20       Impact factor: 2.226

6.  Mediated and moderated effects of neurocognitive impairment on outcomes of treatment for substance dependence and major depression.

Authors:  Matthew J Worley; Susan R Tate; Eric Granholm; Sandra A Brown
Journal:  J Consult Clin Psychol       Date:  2014-03-03

7.  Cognition, commitment language, and behavioral change among cocaine-dependent patients.

Authors:  Efrat Aharonovich; Paul C Amrhein; Adam Bisaga; Edward V Nunes; Deborah S Hasin
Journal:  Psychol Addict Behav       Date:  2008-12

8.  Neurocognition and inhibitory control in polysubstance use disorders: Comparison with alcohol use disorders and changes with abstinence.

Authors:  Thomas P Schmidt; David L Pennington; Stephanie L Cardoos; Timothy C Durazzo; Dieter J Meyerhoff
Journal:  J Clin Exp Neuropsychol       Date:  2016-10-03       Impact factor: 2.475

9.  Evaluation of the Addictions Neuroclinical Assessment (ANA) framework through deep phenotyping of problem drinkers.

Authors:  Steven J Nieto; Erica N Grodin; ReJoyce Green; Lara A Ray
Journal:  Drug Alcohol Depend       Date:  2021-02-13       Impact factor: 4.492

10.  Combined neuroimaging, neurocognitive and psychiatric factors to predict alcohol consumption following treatment for alcohol dependence.

Authors:  Timothy C Durazzo; Stefan Gazdzinski; Ping-Hong Yeh; Dieter J Meyerhoff
Journal:  Alcohol Alcohol       Date:  2008-09-24       Impact factor: 2.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.